 What makes bluebird unique? We're trying to do something that medicine hasn't seen before. A one-time treatment to potentially cure or dramatically transform a genetically lethal disease. I'm going to say that again because that is the fundamental vision of what we're trying to do, which is to dramatically transform through a one-time treatment a genetically lethal disease. So not only is that unique and certainly inspiring from our point of view and gets us to work every single day in a very driven manner, but also the fact that it's doable. We're actually starting to make progress on it. We're working on two diseases at Bluebird, one called ALD, Adrenalucid Dystrophy, which is a lethal childhood disorder that affects the brain. We've treated four boys in Paris that by all accounts, statistically speaking, should have passed away by now and are at home and in the playground. That's unique. That's exciting. You can look at Thalassemia. This is a case where you can't make hemoglobin. You can't make blood. If you don't get transfusions, you also die. Here we've treated a boy who has been dependent on these transfusions since the age of two. And now after a one-time treatment with the therapy I'll walk you through in a minute, has not had a transfusion for many years. This is transformational, living a completely different life. So taking all those things together, that is definitely what we feel makes Bluebird unique. So what makes Bluebird innovative? And I have to say the easiest answer, the most honest answer is the technology that we employ. The how of how we do it. And the way we go about this is something called gene therapy. Gene therapy is a very broad statement. So the type of gene therapy we do is something called viral gene therapy. And that's actually where we take advantage of a virus to go in and deliver therapeutically what we want or need for the disease. And in our case, we actually use something called the lentivirus, which is a derivative of the HIV virus. What we do is we take the goodness out of that virus, we turn it upside down, we make it work for us. So in the diseases I just described, ALD and thalassemia, those are both what's called monogenic diseases. They have a single problem. We know what we need to do in those diseases, and the virus allows us to do it. It allows us to take cells outside the body from those patients in those diseases and then use the HIV virus, or in this case, the lentivirus, to insert a copy of the dysfunctional gene into those cells. So by that way, we're taking advantage of what the bad virus of HIV was good at, which is targeting a cell, infecting it with a gene. But this case, it's the cells we tell it to go after. And in our case, it's also inserting the gene that we want it to insert. So that impact is there, and that's the innovation. But the other aspect of innovation is you can do that one time. You can do it in small scale. But how do you industrialize that? How do you get it to the point where you can manufacture these types of viruses and you can treat many patients? In there lies the other half of our innovation. One thing is getting the science and the initial work done in patients. The next half is how do you expand it? How do you industrialize it? And that is actually what ties to the next question. How is Bluebird able to impact the world on a global basis? And from our perspective, it's very simple. And Bluebird dreams about this on multiple levels. The first level is patient by patient. You heard about a few of these patients that we've treated already. So we feel we're making good progress. It's just the beginning. We're by no means there. But at least we have hope and we have a reason to believe that we can have a dramatic impact on a patient by patient basis. But how do you take that to the next level? How do you go after disease by disease? How do you make sure that access to these types of treatments are not just in the areas that can pay for it but all around the world? Take thalassemia and sickle cell. Those are the most common genetic disorders in the world. Our hope and dream is that we can not only have a treatment for those but that we can deploy them on a global basis. What's next, I can't tell you. But what I can tell you is this platform, this therapeutic modality that we're working on, we have strong hopes for, can do great good in many other diseases on a worldwide basis. But first things first, our vision is to make hope a reality and the best way to do that is to go patient by patient and then after that we hope that global impact is sure to come.